CD274 and non-small cell lung carcinoma: Exosome-based biomarker research in NSCLC has primarily focused on the PD-1/PD-L1 pathway, with exosomal PD-L1 demonstrating significant potential as a non-invasive marker for monitoring immunotherapy responses.